Spyre Therapeutics Shares Fall After RA Drug Fails Monotherapy Threshold

SPY072 Rheumatoid Arthritis Trial Disappoints

Spyre Therapeutics (SYRE) shares dropped 11.7% in pre-open trading following the release of Phase 2 SKYWAY basket trial data for its anti-TL1A antibody candidate, SPY072, in rheumatoid arthritis (RA). Although SPY072 demonstrated statistically significant improvements over placebo, it fell short of the company's internal thresholds required to prioritize it as a standalone RA therapy. Consequently, Spyre announced it would not advance the drug as a monotherapy in this indication.

Market Reacts to Spyre's Pipeline Update

The sell-off reflects significant investor disappointment, as the RA program was among the most closely watched near-term catalysts for the company. Despite this setback, Wedbush maintained its Outperform rating and a $130 price target, signaling that analysts view Spyre's remaining pipeline catalysts, well-funded balance sheet, and robust upcoming readouts as intact. The company still anticipates Phase 2 SKYWAY readouts for SPY072 in psoriatic arthritis and axial spondyloarthritis in Q4 2026, alongside additional data from its SKYLINE ulcerative colitis program in September.

Conclusion

The sharp pre-market decline indicates the market is repricing the near-term risk profile of SPY072's rheumatology franchise. Spyre maintains that the data validates TL1A inhibition as a mechanism and supports the drug’s potential in combination regimens and other autoimmune indications. Future stock stability will likely depend on how investors weigh these remaining 2026 catalysts against the recent setback in RA.

FAQ

Q: Why did Spyre Therapeutics stock decline today?

A: Spyre Therapeutics stock fell after its SPY072 drug for rheumatoid arthritis did not meet internal efficacy thresholds for advancement as a monotherapy, despite showing some improvements.

Q: What is the future outlook for Spyre's pipeline?

A: The company has upcoming Phase 2 readouts for SPY072 in psoriatic arthritis and axial spondyloarthritis in Q4 2026, plus ulcerative colitis data in September, which analysts view as promising.

Source: Investing.com